GALT has updated their NASH-CX presentation. Click here to view the form 8-K and presentation. On March 06, 2019 GALT filed registration statements of a rights offering of common stock and … [Read more...] about GALT Updates NASH-RX Presentation
GALT
GALT Director Sells 30K Shares
Leave a comment and click here to sub for MS Equity Analysis and Swing Moves. A form-4 just filed on 02/04/2019 by Galectin Therapeutics (Nasdaq: GALT) reports that GALT director … [Read more...] about GALT Director Sells 30K Shares
GALT Announces Extension of Retention Bonuses
Leave a comment and click here to sub for MS article alerts and our newsletter! On January 16th, 2019 Galectin Therapeutics (Nasdaq: GALT) board of directors approved the extension of … [Read more...] about GALT Announces Extension of Retention Bonuses
MS Morning Update
Leave a comment and click here to subscribe for MS article alerts and our newsletter! MRK Exercises Option For NGM Bio's Investigational Insulin Sensitizer-NGM313 January 3rd, 2019 MRK … [Read more...] about MS Morning Update
Parallels Between Conatus ENCORE-PH Readout And Galectin Therapeutics Phase-2b Clinical-CX
leave a comment and click here to sub for MS article alerts and our newsletter Introduction MS noticed some insightful parallels between when Conatus Pharmaceuticals (Nasdaq: CNAT) … [Read more...] about Parallels Between Conatus ENCORE-PH Readout And Galectin Therapeutics Phase-2b Clinical-CX
Post-ENCORE-PH Interview With CNAT
Leave a comment and click here to sub for MS article alerts and our newsletter On the heels of the contentious revealing of ENCORE-PH top-line data MS Money Moves decided to go to the source for … [Read more...] about Post-ENCORE-PH Interview With CNAT
A Question about ACRX price decline after Dsuvia approval
Question by deadpool from StockTwits: Q: "how do you feel about ACRX price action today seems like just a red market is tearing everything down. i am hopeful we get back up to 3.30s next week" Thanks … [Read more...] about A Question about ACRX price decline after Dsuvia approval
RSI and How You Can Leverage It
Key Points RSI can help you decide whether you should buy or sell RSI can help identify how undervalued/overvalued the stock is Background RSI; Relative Strength Index is a measure of recent … [Read more...] about RSI and How You Can Leverage It
Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath
Overview Wednesday October 24th, 2018 the stock market was slashed across the board with the DOW erasing all its gains for the year and dripping red. The Nasdaq was hit with equal force. Comments from … [Read more...] about Potentially Lucrative Opportunities Amidst A Stock Market Bloodbath
Market Hasn’t Grasped the Magnitude of GALT Phase1b Keytruda Combo Study
Today September 20th Galectin Therapeutics (NASDAQ: GALT) announced promising results from their phase 1b clinical trial of GR-MD-02 and KEYTRUDA® in Advanced Melanoma and Expansion of the Trial. … [Read more...] about Market Hasn’t Grasped the Magnitude of GALT Phase1b Keytruda Combo Study
You must be logged in to post a comment.